Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis.
The poor prognosis of patients with malignant gliomas is at least partially due to the invasive nature of these tumors. In this study, the authors investigated the possibility that the cysteine protease cathepsin B (CB) is a participant in the process of glial tumor cell invasion. To accomplish this, an immunohistochemical analysis was made of the localization of antibodies to CB in biopsies of five specimens of normal brain, 16 astrocytomas, 33 anaplastic astrocytomas, and 33 glioblastomas multiforme. Staining was scored according to the percentage of positive cells and the intensity of the stain, graded from 0 to 3+. Staining for CB was not seen in any of five samples of normal brain except for occasional neuronal cell bodies and microglia. Only five (31%) of 16 astrocytomas showed a small percentage of positive cells (0.01%-3%) that were stained in a light, diffuse cytoplasmic pattern (1+). Twenty-nine (87.8%) of 33 anaplastic astrocytomas showed positive light, granular staining in 2% to 40% of cells. In anaplastic astrocytoma, the staining within a tumor was heterogeneous with intensities of 1+ (17%), 1+ to 2+ (29%), or 2+ (55%). In contrast, all 33 (100%) glioblastomas were positive in 10% to 90% of cells. The staining was present in a coarse, granular pattern with an intensity of 2+ (12%) or 3+ (88%). Tumor cells infiltrating into brain adjacent to malignant gliomas stained positively in 26 cases that could be evaluated for glioblastoma multiforme; these invading cells frequently followed penetrating blood vessels as typical "secondary structures of Scherer." Moderate to intense CB staining associated with endothelial proliferation in high-grade tumors was also observed, especially in regions of tumor infiltration into adjacent normal brain. These results provide evidence consistent with the hypothesis that CB is functionally significant in the process of tumor invasion and angiogenesis in the clinical progression of the malignant phenotype in astrocytes.
Mikkelsen
T
T
Department of Neurosurgery, Neurology, Henry Ford Hospital, Detroit, Michigan, USA.
Yan
P S
PS
Ho
K L
KL
Sameni
M
M
Sloane
B F
BF
Rosenblum
M L
ML
D000911:Antibodies, Monoclonal; D001254:Astrocytoma / Q000473:pathology; D001921:Brain / Q000166:cytology; D001932:Brain Neoplasms / Q000098:blood supply / Q000473:pathology*; D002401:Cathepsin B / Q000032:analysis*; D002455:Cell Division; D003593:Cytoplasm / Q000473:pathology; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000473:pathology; D005909:Glioblastoma / Q000473:pathology; D005910:Glioma / Q000098:blood supply / Q000473:pathology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D017628:Microglia / Q000648:ultrastructure; D009361:Neoplasm Invasiveness; D009389:Neovascularization, Pathologic / Q000473:pathology; D009474:Neurons / Q000648:ultrastructure; D013194:Staining and Labeling
D000911:Antibodies, Monoclonal; D002401:Cathepsin B